The Long COVID-19 Wearable Device Study
Long COVID, Postural Orthostatic Tachycardia Syndrome, Dysautonomia
About this trial
This is an interventional basic science trial for Long COVID
Eligibility Criteria
Inclusion Criteria: Is at least 18 years old. Has a self/and or physician diagnosis of: Long COVID (based on the WHO working definition), ME/CFS (myalgic encephalomyelitis / chronic fatigue syndrome, self-diagnosis based on IOM criteria), and/or POTS (Postural Orthostatic Tachycardia Syndrome). Is interested in tools to manage ME/CFS, POTS, and/or Long COVID symptoms. Owns a wearable device they are willing to use for this study or does not own a device and agrees to utilize a study-provided one. Agrees to wear the device throughout the study period, share the data with the study, and sync data at least weekly. Has access to a smartphone or tablet to enable syncing wearable data and viewing device feedback. Agrees to disclose involvement in other ME/CFS, POTS, and/or Long COVID interventions such as medical treatment, self-management, and other interventional studies. Agrees to complete at least 75% of the study surveys. Exclusion Criteria: As long as they meet inclusion there is no exclusion
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Other
Other
Other
Other
Control: study provided wearables
Treatment: study provided wearables
Control: self provided wearables
Treatment: self provided wearables
Following consent and the completion of the baseline assessments the control group will receive basic education on symptom management. At the 3 month timepoint they will be prompted to order their device and receive enhanced education that will provide information on how wearable devices can be used to monitor and manage symptoms.
Following consent and the completion of the baseline assessments the treatment group will be prompted to order their device and receive basic education on symptom management along with the enhanced education on wearable devices.
Following consent and the completion of the baseline assessments the control group will receive basic education on symptom management. At the 3 month timepoint they will be receive enhanced education that will provide information on how wearable devices can be used to monitor and manage symptoms.
Following consent and the completion of the baseline assessments the treatment group will receive basic education on symptom management along with the enhanced education on wearable devices.